BOSTON ( TheStreet) -- The November calendar of biotech and drug stock events.

Nov. 3

Earnings: Arena Pharmaceuticals (ARNA - Get Report) , MannKind (MNKD Neurocrine Biosciences (NBIX

Nov. 4

Earnings: Ironwood Pharma (IRWD , Jazz Pharma (JAZZ , Halozyme Therapeutics (HALO , Exelixis (EXEL , Myriad Genetics (MYGN , Pharmacylics (PCYC , Regeneron Pharma (REGN

FDA releases briefing documents for Oncologic Drug Advisory Committee meeting scheduled for Nov. 6: Rockwell Medical  (RMTI - Get Report) (Triferic) and Novartis (NVS (Faridak.)

Nov. 5

Earnings: Actavis (ACT Regulus Therapeutics (RGLS - Get Report) , Vivus (VVUS  , Alnylam Pharma (ALNY

FDA approval decision: Aeterna Zentaris (AEZS Macrilen for growth hormone deficiency.

The Medicines Co. (MDCO Investor/Analyst meeting.

Nov. 6

Earnings: Amarin (AMRN , AstraZeneca (AZN , Epizyme (EPZM - Get Report) , Hyperion Therapeutics (HPTX   Keryx Pharma (KERX , Medivation (MDVN , NewLink Genetics (NLNK , Raptor Pharma (RPTP , Tekmira Pharma (TKMR , Spectrum Pharma (SPPI , Sarepta Therapeutics (SRPT

FDA Oncologic Drugs Advisory Committee: Rockwell Medical (Triferic) and Novaris (Faridak.)

Nov. 7

Earnings: Agios Pharma (AGIO - Get Report) , Intercept Pharma (ICPT

Nov. 10

Intercept Pharma Analyst/Investor Day.

Nov. 13

Earnings: Retrophin (RTRX - Get Report)

Nov. 18

AstraZeneca Analyst/Investor Day

Ligand (LGND Analyst/Investor Day

Nov. 19 

FDA approval decision: Genentech/Roche  (RHHBY Avastin for recurrent, platinum-resistant ovarian cancer.

Nov. 26 

FDA approval decision: Avanir Pharma (AVNR  AVP-825 for migraine.

November Medical Meetings:

Nov. 2-7: Obesity Week: Orexigen Therapeutics (OREX , Arena Pharma ARNA

Nov. 7-11: American Association for the Study of Liver Disease (AASLD): Gilead Sciences (GILD - Get Report) , Merck (MRK - Get Report) , Bristol-Myers Squibb (BMY , Abbvie ABBV, Enanta Pharma (ENTA , Arrowhead Research (ARWR - Get Report) , Conatus Pharma (CNAT , Genfit ALGFT, Alnylam Pharma (ALNY

Nov. 9: International Gynecologic Cancer Society: Oxigene (OXGN fosbretabulin+Avastin phase II recurrent ovarian cancer.

Nov. 11-16: American Society of Nephrology: Acceleron Pharma (XLRN

Nov. 13-16: Society of Neuro-Oncology annual meeting: Celldex Therapeutics (CLDX , ImmunoCellular Therapeutics (IMUC

Nov. 15-19: American Heart Association Scientific Sessions: Merck, NeoStem (NBS , Regeneron Pharma  

Nov. 18-21: EORTC-NCI-AACR: Agios Pharma, Bind Therapeutics (BIND , Clovis Oncology 

Clinical Data: 

XOMA (XOMA Gevokizumab (Behcet's Syndrome), Achillion Pharma (ACHN ACH-3422 (hepatitis C)

Source: BioMedTracker.com, company reports and TheStreet research.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.